September 19-22, 2022 – Boston, MA
Presentation: Developing Versatile T-cell Therapies Against Extracellular, Intracellular & Planted Targets for the Treatment of Solid Tumors
Panel Discussion: New Frontiers in Cell Therapy – Optimizing Combined Approaches for Greater Persistence
Scientific Reports. 15 July 2022: Chang Liu, Hong Liu, Moumita Dasgupta, Lance M. Hellman, Xiaogang Zhang, Kai Qu, Hui Xue, Yun Wang, Fenling Fan, Qi Chang, Duo Yu, Linhu Ge, Yu Zhang, Ziyou Cui, Pengbo Zhang, Bradley Heller, Hongbing Zhang, Bingyin Shi, Brian M. Baker & Cheng Liu
Journal of Cancer Research and Clinical Oncology. 1 July 2022: Pengcheng He, Haibo Liu , Bryan Zimdahl, Jie Wang, Minna Luo, Qi Chang, Fangzhou Tian, Fan Ni, Duo Yu, Huasheng Liu, Limei Chen, Huaiyu Wang, Mei Zhang, Stephan A Grupp, Cheng Liu
Figure 1: Overview of the TCRm-AFP/HLA-A*02 complex with the heavy and light chains of the TCRm Emeryville, California, August 3, 2022 — Eureka Therapeutics, Inc.,
July 26-28, 2022 – Embassy Suites Boston Logan Airport, Boston, MA
Harnessing Gamma Delta TCR Signaling and Alpha Beta T Cell Biology for Cancer Therapy
June 29-30, 2022 – Boston, MA
Developing a Versatile T-Cell Engineering Platform Capable of Accessing Extracellular, Intracellular and Planted Targets for the Treatment of Solid Tumors
June 27-29, 2022 – Boston, MA
Improving T Cell Performance in Solid Tumors with an Engineered Antibody T-Cell Receptor (AbTCR)
May 2-6, 2022 – Hynes Convention Center, Boston, MA
Roundtable: Targeting Intracellular Antigens – Challenges and Opportunities
November 16-18, 2021 – Virtual
Overcoming Solid Tumor Challenges with ARTEMIS Antibody Redirected T-Cell Therapy
September 29-30, 2021 – Virtual
CD19/CD22 Dual-Targeting ARTEMIS Antibody Redirected TCR T-Cell Therapy for the Treatment of Hematological Malignancies
Alexa Willson has served as the Chief Financial Officer of Eureka Therapeutics since August 2022. Prior to joining the company, She was a Managing Partner of Cloudstone Venture Capital, an early-stage healthtech venture firm since October 2020. Cloudstone is also an investor of Eureka Therapeutics.
Ms. Willson has over 25 years of experience advising public and private companies on corporate finance, strategy, capital raising, valuation, mergers & acquisitions, and other matters. She has founded and run a midmarket investment banking boutique and worked with large Wall Street investment banks, including Kidder Peabody and Drexel Burnham.
Ms. Willson has served on private and non-profit boards and investment committees in various capacities. She teaches financial literacy. Ms. Willson holds a BA from Harvard and an MBA from Stanford Graduate School of Business.